INTERNATIONAL JOURNAL OF CANCER-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer 经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿） 该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246830, encodeId=99012246830dc, content=稿约明确说明不收MR文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Jan 06 14:30:30 CST 2025, time=2025-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省)]

2021-09-04 凶巴巴恰北北怪兽

7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好

326 19

展开19条回复

[GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer 经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿） 该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246830, encodeId=99012246830dc, content=稿约明确说明不收MR文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Jan 06 14:30:30 CST 2025, time=2025-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省)]

2022-03-04 1221c8e5m44(暂无昵称)

审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3
偏重的研究方向：Meta;epidemiology;Cancer
经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。

95 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer 经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿） 该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246830, encodeId=99012246830dc, content=稿约明确说明不收MR文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Jan 06 14:30:30 CST 2025, time=2025-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省)]

2025-02-24 ms9000000156680607 来自重庆

偏重的研究方向：肿瘤;Environmental Research;Cancer
经验分享：请问一下under review是内审还是外审啊？

9 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer 经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿） 该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246830, encodeId=99012246830dc, content=稿约明确说明不收MR文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Jan 06 14:30:30 CST 2025, time=2025-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省)]

2024-11-30 ms2000001750570964 来自广西

审稿速度:3.0
偏重的研究方向：临床试验
经验分享：2024..9.5投 9.10under review
至今还在UR
都说这个杂志速度快
看了一圈没一个人比我久的我都i想催稿了

23 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer 经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿） 该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246830, encodeId=99012246830dc, content=稿约明确说明不收MR文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Jan 06 14:30:30 CST 2025, time=2025-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省)]

2025-01-12 ms5000002977722138 来自上海

审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿）
该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费

12 0

[GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer 经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿） 该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246830, encodeId=99012246830dc, content=稿约明确说明不收MR文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Jan 06 14:30:30 CST 2025, time=2025-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省)]

2025-01-06 匿名用户

稿约明确说明不收MR文章

16 0

[GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer 经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿） 该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246830, encodeId=99012246830dc, content=稿约明确说明不收MR文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Jan 06 14:30:30 CST 2025, time=2025-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省)]

2020-09-17 da-xiang

审稿速度:6.0 | 投稿命中率:25.0
经验分享：分享一下我的投稿经历
2020.5.9 submitted to the journal
2020.5.11 under evaluation
2020.5.11 under review
2020.6.7 Awaiting descision
2020.6.11 Major revision
2020.8.10 Revision submitted
2020.8.10 under evaluation
2020.8.13 under review
2020.9.5 Awaiting descision
2020.9.9 Accepted
首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。

5 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer 经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿） 该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246830, encodeId=99012246830dc, content=稿约明确说明不收MR文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Jan 06 14:30:30 CST 2025, time=2025-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省)]

2020-09-04 Nevermorx

有没有人投综述呀

215 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer 经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿） 该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246830, encodeId=99012246830dc, content=稿约明确说明不收MR文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Jan 06 14:30:30 CST 2025, time=2025-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省)]

2022-04-26 ms9000000399989409

偏重的研究方向：肿瘤;Cancer;临床
经验分享：问一下大家under evaluation都持续几天呢?

327 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3 偏重的研究方向：Meta;epidemiology;Cancer 经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer 经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿） 该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246830, encodeId=99012246830dc, content=稿约明确说明不收MR文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Jan 06 14:30:30 CST 2025, time=2025-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省)]

2023-12-29 ms3000001161396804 来自黑龙江省

偏重的研究方向：DNA损伤修复
经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢

317 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务